Protective effects of saizen in combination with stilamin on intestinal mucosa of a rabbit model of severe acute pancreatitis.
OBJECTIVE
The objective of this study was to investigate whether the regimen of saizen, a recombinant human somatropin, in combination stilamin, a somatostatin analog, exerts synergistic effect on intestinal mucosa of a rabbit model of severe acute pancreatitis.


METHODS
The rabbits were randomly divided into 3 groups: group A without any treatment, group B with single treatment of stilamin, and group C with treatment of saizen combined with stilamin. The blood levels of D-lactate, insulinlike growth factor 1, prealbumin, and albumin were detected at the 6th, 12th, 24th, 48th, and 72nd hours after modeling. The pathological changes in terms of the villus height, crypt depth, and mucosal thickness were observed. The caspase 3 expression and apoptotic indices were evaluated.


RESULTS
The blood levels of D-lactate at the 48th hour; insulinlike growth factor 1 at the 24th and 48th hours; prealbumin at the 24th, 48th, and 72nd hours; and albumin at the 48th hour in group C were significantly higher than these in the other 2 groups. Pathological changes in group C were slighter; the level of caspase 3 and apoptotic index in group C were significantly lower than those in the other 2 groups.


CONCLUSIONS
The combination of saizen with stilamin can enhance intestinal mucosa barrier function.
Department of gastroenterology, Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China.
Yan
Y
Lu
Yanmei
Y
Yu
Meilan
M
Yang
Hui
H
Liu
Bin
B
Li
Hongwei
H
Xu
D000208:Acute Disease; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D053148:Caspase 3 / Q000378:metabolism; D019610:Cytoprotection; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D019382:Human Growth Hormone / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D019344:Lactic Acid / Q000097:blood; D010195:Pancreatitis / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D011228:Prealbumin / Q000378:metabolism; D020011:Protective Agents / Q000494:pharmacology*; D011817:Rabbits; D011994:Recombinant Proteins / Q000494:pharmacology; D012720:Severity of Illness Index; D013004:Somatostatin / Q000494:pharmacology*; D013656:Taurocholic Acid; D013997:Time Factors
D015415:Biomarkers; D011228:Prealbumin; D020011:Protective Agents; D011994:Recombinant Proteins; C548904:insulin-like growth factor-1, rat; D019382:Human Growth Hormone; D019344:Lactic Acid; D013004:Somatostatin; D013656:Taurocholic Acid; D007334:Insulin-Like Growth Factor I; C505410:Casp3 protein, rat; D053148:Caspase 3